Osanni Bio raised $190 million in a Series B to advance its therapeutics pipeline and scale its drug discovery platform.
- Amount
- $190M
- Stage
- Series B
- Announced
- 23 June 2026
- Lead
- Patient Square Capital
- Other investors
- Horowitz Group, Invus Opportunities, Retinal Degeneration Fund
- Use of funds
- Advance the current pipeline of multiple programs and scale its discovery and development process.
- Checked
- Amount and date matched across 3 press sources